HighTide Therapeutics, Inc. (HKG:2511)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.910
-0.040 (-1.36%)
May 20, 2025, 4:08 PM HKT
-54.95%
Market Cap 1.52B
Revenue (ttm) n/a
Net Income (ttm) -406.29M
Shares Out 514.77M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,539,500
Average Volume 2,926,625
Open 2.960
Previous Close 2.950
Day's Range 2.880 - 3.200
52-Week Range 0.720 - 7.500
Beta n/a
RSI 66.51
Earnings Date May 28, 2025

About HighTide Therapeutics

HighTide Therapeutics, Inc., an biopharmaceutical company, engages in the discovery, research and development, and commercialization of therapies for the treatment of metabolic and digestive diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis; in phase III clinical trial to treat type 2 diabetes mellitus; is in phase II clinical trial to treat severe hypertriglyceridemia; and in phase II clinical trial to treat primary sclerosing cholangit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 70
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2511
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.